Eyenovia is a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indications. Co.'s drug-device therapeutic programs include MicroPine, MicroLine and Mydcombi. MicroPine is Co.'s topical therapy for the treatment of progressive myopia, a back-of-the-eye ocular disease associated with pathologic axial elongation and sclero-retinal stretching. MicroLine is Co.'s investigational pharmacologic treatment for presbyopia. Mydcombi is Co.'s fixed combination formulation of tropicamide-phenylephrine for mydriasis. The EYEN average annual return since 2018 is shown above.
The Average Annual Return on the EYEN average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether EYEN average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the EYEN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|